Effect of metformin on the volume of cysts and kidneys in poly-cystic kidney disease patients

Evaluating the effect of metformin on cyst volume and kidney volume in patients with Autosomal dominant polycystic kidney disease (ADPKD)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013021912527N1

Enrollment

Registered

2014-10-25

Start date

2014-02-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic kidney disease. Polycystic Kidney, autosomal dominant

Interventions

Patients will take 1 tablet of metformin 500 mg (Rogin Daroo Company) daily for the first week, two tablets daily for the second week and three tablets daily thereafter up to six months..

Treatment - Drugs

Patients will take 1 tablet of metformin 500 mg (Rogin Daroo Company) daily for the first week, two tablets daily for the second week and three tablets daily thereafter up to six months.

Eligibility

Sex/Gender

All

Age

14 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Serum creatinine less than 1.4mg/dL at the beginning of the study; signing the informed consent form Exclusion criteria: previous history of metformin use; allergy to metformin; any side effect during the intervention which prevents the patient from continuing the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Volume of cyst. Timepoint: Before and after intervention. Method of measurement: MRI.;Kidney volume. Timepoint: Before and after intervention. Method of measurement: MRI.	—

Secondary

Measure	Time frame
Serum creatinine. Timepoint: Before and after intervention. Method of measurement: Jaffe method.;24h-Urine protein. Timepoint: Before and after intervention. Method of measurement: Laboratory.;Serum IL-6. Timepoint: Before and after intervention. Method of measurement: kit.;Serum CRP. Timepoint: Before and after intervention. Method of measurement: Kit.;GFR. Timepoint: Before and after intervention. Method of measurement: Calculation.	—

Measure

Time frame

Serum creatinine. Timepoint: Before and after intervention. Method of measurement: Jaffe method.;24h-Urine protein. Timepoint: Before and after intervention. Method of measurement: Laboratory.;Serum IL-6. Timepoint: Before and after intervention. Method of measurement: kit.;Serum CRP. Timepoint: Before and after intervention. Method of measurement: Kit.;GFR. Timepoint: Before and after intervention. Method of measurement: Calculation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farrokhlagha Ahmadi

Nephrology Resaerch Center, Tehran University of Medical Sciences

ahmadifa@tums.ac.ir+98 21 6658 1568

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026